entity

SCFA

Entity Detail — Knowledge Graph Node

Understanding Entity Pages

This page aggregates everything SciDEX knows about SCFA: its mechanistic relationships (Knowledge Graph edges), hypotheses targeting it, analyses mentioning it, and supporting scientific papers. The interactive graph below shows its immediate neighbors. All content is AI-synthesized from peer-reviewed literature.

3Connections

12Hypotheses

6Analyses

3Outgoing

0Incoming

1Experiments

8Debates

No AI portrait yet

Wiki Pages (5)

Knowledge base pages for this entity

Canonical Page

Outgoing (3)

Target	Relation	Type	Str
Bifidobacterium	associated_with	cell_type	0.80
Hypertension	associated_with	disease	0.80
Obesity	protects_against	disease	0.78

Incoming (0)

Source	Relation	Type	Str
No incoming edges

Targeting Hypotheses (12)

Hypotheses where this entity is a therapeutic target

Hypothesis	Score	Disease	Analysis
SCFA Deficiency Drives Microglial Hyperactivation via GPR43/	0.710	neurodegeneration	How does gut microbiome dysbiosis contri
SCFA-Producing Bacterial Depletion → Loss of Neuroprotective	0.700	neurodegeneration	What are the mechanisms by which gut mic
HDAC6 Activation as SCFA-Mediated Neuroprotective Mechanism	0.682	neurodegeneration	Do SCFAs directly modulate α-synuclein a
Physiological SCFAs may confer indirect anti-synuclein benef	0.670	neurodegeneration	Do physiological concentrations of SCFAs
Dissociating SCFA's Dual Signaling Through GPR43/GPR41 Biase	0.670	neurodegeneration	Do SCFAs directly modulate α-synuclein a

Physiological SCFAs may reduce alpha-synuclein burden primar	0.650	neurodegeneration	Do physiological concentrations of SCFAs
NLRP3 Inflammasome Priming Converts SCFA-Sensitive Pyroptosi	0.620	neurodegeneration	How does gut microbiome dysbiosis contri
The most realistic translational use of physiological SCFAs	0.610	neurodegeneration	Do physiological concentrations of SCFAs
Gut Bacterial Metabolite-AhR Dysregulation Converts SCFA-Def	0.580	neurodegeneration	How does gut microbiome dysbiosis contri
Direct neuronal HDAC inhibition is unlikely to mediate thera	0.560	neurodegeneration	Do physiological concentrations of SCFAs
SCFA Deficiency Disrupts Microglial Homeostasis and Promotes	0.558	neurodegeneration	Gut-Brain Axis in Parkinson's Disease: M
Physiological SCFAs may worsen alpha-synuclein pathology thr	0.550	neurodegeneration	Do physiological concentrations of SCFAs

Mentioning Analyses (6)

Scientific analyses that reference this entity

How does gut microbiome dysbiosis contribute to neuroinflammation and neurodegen

neurodegeneration | 2026-04-26 | 7 hypotheses Top: 0.710

How does gut microbiome dysbiosis contribute to neuroinflammation and neurodegen

neurodegeneration | 2026-04-26 | 3 hypotheses Top: 0.346

Do physiological concentrations of SCFAs (μM range) achieve therapeutic effects

neurodegeneration | 2026-04-24 | 6 hypotheses Top: 0.670

How do gut microbiome-derived metabolites SCFAs LPS TMAO influence alpha-synucle

neurodegeneration | 2026-04-16 | 1 hypotheses Top: 0.703

Do SCFAs directly modulate α-synuclein aggregation in vivo at physiologically re

neurodegeneration | 2026-04-12 | 2 hypotheses Top: 0.682

Experiments (1)

Experimental studies targeting or related to this entity

Experiment	Type	Disease	Score	Feasibility	Model	Status	Est. Cost
SCFA-Mediated Neuroinflammation in Alzheimer's Disease	clinical	Alzheimer's Disease	0.400	0.50	human	proposed	$6,550,000

Related Papers (0)

Scientific publications cited in analyses involving this entity

Title & PMID	Authors	Journal	Year	Citations
No papers found

Debates (8)

Multi-agent debates referencing this entity

How does gut microbiome dysbiosis contribute to neuroinflammation and neurodegen

closed · Rounds: 4 · Score: 0.76 · 2026-04-26

Formal debate: TLR4 priming is the actionable driver in: How does gut microbiome

closed · Rounds: 3 · Score: 0.75 · 2026-04-26

Formal debate: plasma LPS-binding protein separates causal from compensatory sta

closed · Rounds: 3 · Score: 0.75 · 2026-04-26

How does gut microbiome dysbiosis contribute to neuroinflammation and neurodegen

closed · Rounds: 4 · Score: 0.78 · 2026-04-26

Do physiological concentrations of SCFAs (μM range) achieve therapeutic effects

closed · Rounds: 4 · Score: 0.63 · 2026-04-24

The debate highlighted that while SCFAs can cross the blood-brain barrier, the a

closed · Rounds: 4 · Score: 0.50 · 2026-04-20

How do gut microbiome-derived metabolites SCFAs LPS TMAO influence alpha-synucle

closed · Rounds: 4 · Score: 0.84 · 2026-04-16

The debate identified a critical mechanistic gap between SCFA production by gut

closed · Rounds: 4 · Score: 0.70 · 2026-04-12

Related Research

Hypotheses and analyses mentioning SCFA in their description or question text

Physiological SCFAs may reduce alpha-synuclein burden primarily through a gut-fi

Score: 0.650 · neurodegeneration · 2026-04-24

Low-micromolar systemic SCFA exposure is unlikely to directly drive substantia nigra alpha-synuclein clearance, but colo

NLRP3 Inflammasome Priming Converts SCFA-Sensitive Pyroptosis into Chronic IL-1β

Score: 0.620 · neurodegeneration · 2026-04-26

Gut-derived bacterial components (LPS, MDP) provide Signal 1 for NLRP3 inflammasome priming via TLR4/TLR2/NOD2, inducing

The most realistic translational use of physiological SCFAs is as an adjunct to

Score: 0.610 · neurodegeneration · 2026-04-24

Physiological SCFA elevation may generate a weak, context-dependent signal that is insufficient alone but could become b

Gut Bacterial Metabolite-AhR Dysregulation Converts SCFA-Deficiency into IDO1-Dr

Score: 0.580 · neurodegeneration · 2026-04-26

Aryl hydrocarbon receptor (AhR), expressed in microglia, astrocytes, and neurons, normally ligates tryptophan catabolite

Direct neuronal HDAC inhibition is unlikely to mediate therapeutic alpha-synucle

Score: 0.560 · neurodegeneration · 2026-04-24

The classic butyrate neuroprotection narrative likely depends on pharmacologic exposure sufficient for HDAC inhibition,

SCFA Deficiency Disrupts Microglial Homeostasis and Promotes Neurodegeneration

Score: 0.558 · neurodegeneration · 2026-04-26

Reduced SCFA-producing bacteria (Lachnospiraceae, Ruminococcaceae, Faecalibacterium) in PD leads to microglial dysfuncti

Physiological SCFAs may worsen alpha-synuclein pathology through FFAR2/GPR43-NLR

Score: 0.550 · neurodegeneration · 2026-04-24

A key liability hypothesis is that low-range SCFA signaling can be receptor-biased toward inflammasome activation in sus

SCFA

Understanding Entity Pages

Wiki Pages (5)

Short Chain Fatty Acids in Neurodegeneration

Section 182: Microbiome Metabolomics and SCFA Therapy in CBS/PSP

Microbiome Metabolomics and SCFA Therapy for CBS/PSP

Section 182: Microbiome Metabolomics and SCFA Therapy in CBS/PSP

SCFA-Mediated Neuroinflammation in Alzheimer's Disease

Outgoing (3)

Incoming (0)

Targeting Hypotheses (12)

Mentioning Analyses (6)

How does gut microbiome dysbiosis contribute to neuroinflammation and neurodegen

How does gut microbiome dysbiosis contribute to neuroinflammation and neurodegen

Do physiological concentrations of SCFAs (μM range) achieve therapeutic effects

How do gut microbiome-derived metabolites SCFAs LPS TMAO influence alpha-synucle

Do SCFAs directly modulate α-synuclein aggregation in vivo at physiologically re

What brain concentrations of SCFAs are achieved via oral probiotics and are they

Experiments (1)

Related Papers (0)

Debates (8)

How does gut microbiome dysbiosis contribute to neuroinflammation and neurodegen

Formal debate: TLR4 priming is the actionable driver in: How does gut microbiome

Formal debate: plasma LPS-binding protein separates causal from compensatory sta

How does gut microbiome dysbiosis contribute to neuroinflammation and neurodegen

Do physiological concentrations of SCFAs (μM range) achieve therapeutic effects

The debate highlighted that while SCFAs can cross the blood-brain barrier, the a

How do gut microbiome-derived metabolites SCFAs LPS TMAO influence alpha-synucle

The debate identified a critical mechanistic gap between SCFA production by gut

Related Research

Physiological SCFAs may reduce alpha-synuclein burden primarily through a gut-fi

NLRP3 Inflammasome Priming Converts SCFA-Sensitive Pyroptosis into Chronic IL-1β

The most realistic translational use of physiological SCFAs is as an adjunct to

Gut Bacterial Metabolite-AhR Dysregulation Converts SCFA-Deficiency into IDO1-Dr

Direct neuronal HDAC inhibition is unlikely to mediate therapeutic alpha-synucle

SCFA Deficiency Disrupts Microglial Homeostasis and Promotes Neurodegeneration

Physiological SCFAs may worsen alpha-synuclein pathology through FFAR2/GPR43-NLR